Advances in the treatment of coronary artery disease remained steady in 2025, as in recent years, but the past 12 months also ...

A new study supports strict adherence to guideline-recommended low-density lipoprotein cholesterol (LDL-C) targets following ...

A recent opinion paper concluded that timely revascularization and dual antiplatelet therapy (DAPT) are crucial in the ...

AS Philippine lawmakers evaluate policies on medical cannabis, a recent study’s conclusions suggest that while cannabinoids may hold promise in specific contexts, their broader medical use remains a ...

Drs Harrington and Gibson’s annual review of cardiovascular medicine: ACS guidelines, antiplatelet management, GLP-1s, and ...

Hoffmann-La Roche Limited (Roche Canada) is proud to announce that Health Canada has granted market authorization for TNKase® (tenecteplase), a thrombolytic (clot-dissolving) agent, effective November ...

Assessments used to calculate cardiovascular disease risk in the general population may not have the same predictive power ...

Heart attack care is entering a phase where machines do not just assist doctors, they anticipate the next move. A new ...

Detailed price information for Esperion Theraptc (ESPR-Q) from The Globe and Mail including charting and trades.

Bayer receives Japanese approval for finerenone to treat patients with chronic heart failure: Berlin Tuesday, December 23, 2025, 14:00 Hrs [IST] Bayer announced that Japan’s Min ...

The approval marks the first new stroke treatment authorized in nearly 27 years, offering an additional option for managing acute ischemic stroke in Canada. MISSISSAUGA, ON, Dec. 17, 2025 /CNW/ - ...

Background The role of mineralocorticoid receptor antagonists (MRAs) in acute myocardial infarction (MI) remains controversial, with conflicting evidence from landmark trials. We aimed to assess the ...